Amyndas: Complement shutdown

Amyndas developing super compstatins for complement-mediated disorders

Transatlantic sister companies Amyndas Pharmaceuticals S.A. and Amyndas Pharmaceuticals LLC are developing therapies to treat complement-mediated disorders that could be more potent than other complement inhibitors, potentially opening up new indications.

Lead candidate Amanden comes from a class of synthetic analogs of the peptidic complement 3 (C3) inhibitor compstatin, which the company calls super compstatins.

According to founder John Lambris, Amanden is up to several orders of magnitude more potent than first generation compstatin-derived synthetic peptide C3 inhibitors.

The first

Read the full 771 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE